The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers
- 1 January 1985
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 28 (6) , 705-708
- https://doi.org/10.1007/bf00607920
Abstract
Summary BAY m1099 (a 1-deoxynojirimycin derivative) is a glucose analogue which is an α-glucosidase inhibitor. Its effects on post-prandial blood glucose and insulin levels was compared with a placebo in 12 healthy male volunteers (6 Blacks and 6 Whites). It produced a similar, significant depression of post-prandial blood glucose and insulin leveles when the groups were assessed separately and when the data were pooled. Although blood insulin levels in Whites were higher than in Blacks, as previously reported, the difference was not statistically significant and did not appear to influence the response to the drug. BAY 1099 produced no objective or subjective untoward effects and appears to warrant further investigation as an adjuvant to dietary control of diabetes mellitus.Keywords
This publication has 6 references indexed in Scilit:
- Inhibition of starch absorption by tendamistate (an alpha-amylase inactivator).1983
- Inhibition of N-linked complex oligosaccharide formation by 1-deoxynojirimycin, an inhibitor of processing glucosidases.Journal of Biological Chemistry, 1982
- Glucosidase-Inhibitoren aus BazillenThe Science of Nature, 1979
- Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.BMJ, 1979
- Decrease in Postprandial Insulin and Glucose Concentrations by Guar and PectinAnnals of Internal Medicine, 1977
- Metabolic Response to Oral Glucose in Healthy South African White, Indian, and African SubjectsBMJ, 1969